NYMOX Announces Trading Resumed and New Listing on OTCQB Market
Nymox Pharmaceutical (NYMXF) has announced the resumption of its stock trading on the OTCQB Venture Market, representing an upgrade from its previous listing tier. This new listing makes the stock eligible for proprietary broker-dealer quotations. The company's president, Paul Averback, expressed gratitude towards the OTC teams for their guidance during the transition process and thanked shareholders and investors for their patience and support. He emphasized the company's focus on advancing prostate treatments to address the market's need for safer and more effective solutions.
Nymox Pharmaceutical (NYMXF) ha annunciato la ripresa delle contrattazioni delle sue azioni sul OTCQB Venture Market, rappresentando un miglioramento rispetto al precedente livello di quotazione. Questa nuova quotazione rende le azioni idonee per le quotazioni fornite da broker-dealer proprietari. Il presidente dell'azienda, Paul Averback, ha espresso gratitudine verso i team OTC per la loro guida durante il processo di transizione e ha ringraziato gli azionisti e gli investitori per la loro pazienza e supporto. Ha sottolineato l'impegno dell'azienda nell'avanzamento dei trattamenti per la prostata per affrontare la necessità del mercato di soluzioni più sicure ed efficaci.
Nymox Pharmaceutical (NYMXF) ha anunciado la reanudación de la negociación de sus acciones en el OTCQB Venture Market, lo que representa una mejora con respecto a su nivel de cotización anterior. Esta nueva cotización hace que las acciones sean elegibles para las cotizaciones de corredores-dealer propietarios. El presidente de la empresa, Paul Averback, expresó su gratitud hacia los equipos de OTC por su orientación durante el proceso de transición y agradeció a los accionistas e inversores por su paciencia y apoyo. Subrayó el enfoque de la empresa en el avance de los tratamientos para la próstata para abordar la necesidad del mercado de soluciones más seguras y efectivas.
Nymox Pharmaceutical (NYMXF)는 OTCQB Venture Market에서 주식 거래가 재개되었다고 발표하며, 이는 이전 상장 등급에서의 업그레이드를 나타냅니다. 이 새로운 상장으로 인해 주식은 독점적인 중개인-딜러 인용을 받을 수 있게 되었습니다. 회사의 사장인 Paul Averback는 전환 과정 동안의 안내에 대해 OTC 팀에 감사의 말씀을 전하며, 주주와 투자자들에게 그들의 인내와 지원에 감사했습니다. 그는 회사가 시장의 안전하고 효과적인 솔루션에 대한 요구를 해결하기 위해 전립선 치료의 발전에 집중하고 있음을 강조했습니다.
Nymox Pharmaceutical (NYMXF) a annoncé la reprise de la cotation de ses actions sur le OTCQB Venture Market, représentant une amélioration par rapport à son précédent niveau de cotation. Cette nouvelle cotation rend les actions éligibles pour les cotations de courtiers-délégués propriétaires. Le président de l'entreprise, Paul Averback, a exprimé sa gratitude envers les équipes OTC pour leur orientation durant le processus de transition et a remercié les actionnaires et investisseurs pour leur patience et leur soutien. Il a souligné l'engagement de l'entreprise à faire progresser les traitements de la prostate pour répondre aux besoins du marché en solutions plus sûres et plus efficaces.
Nymox Pharmaceutical (NYMXF) hat die Wiederaufnahme des Handels seiner Aktien am OTCQB Venture Market bekannt gegeben, was ein Upgrade gegenüber der vorherigen Listing-Ebene darstellt. Diese neue Listing macht die Aktie für eigene Broker-Dealer-Notierungen berechtigt. Der Präsident des Unternehmens, Paul Averback, drückte seine Dankbarkeit gegenüber den OTC-Teams für deren Unterstützung während des Übergangsprozesses aus und dankte den Aktionären und Investoren für ihre Geduld und Unterstützung. Er betonte den Fokus des Unternehmens auf die Weiterentwicklung von Prostatabehandlungen, um den Bedürfnissen des Marktes nach sichereren und effektiveren Lösungen gerecht zu werden.
- Upgraded listing to OTCQB Venture Market from previous tier
- Stock now eligible for proprietary broker-dealer quotations
- None.
IRVINE Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the Company's stock has resumed trading under the symbol NYMXF on the Over the Counter QB (OTCQB®) Venture Market. This is a higher level tier from the Company's prior listing. With the new OTCQB listing, Nymox’s stock is now eligible for proprietary broker-dealer quotations.
Paul Averback, President of Nymox said, "We are delighted that Nymox has now qualified to be on the OTCQB exchange. The Company thanks the professional teams at the OTC who provided guidance and helped to make the process run as smoothly as possible. Our shareholders and investors have been very patient and supportive,-- and we thank our countless supporters, colleagues and friends for their many important contributions to Nymox's work."
"We all want to see the Company's important advances in prostate treatments make further progress to become available to the public. It is well known that there is a great unfulfilled need for safer and more effective prostate disease treatments," he said.
About NYMOZARFEX (TM) (Fexapotide)
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials for BPH and for early stage prostate cancer involving overall more than 1750 patients with over 1600 injections administered including over 1200 NYMOZARFEX™ administrations. NYMOZARFEX™ has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.
For more information please contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of NYMOZARFEX™ to treat BPH and prostate cancer and the estimated timing of further developments for NYMOZARFEX™. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on NYMOZARFEX™, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of NYMOZARFEX™. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2023, and its Quarterly Reports.
For Further Information Contact:
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
FAQ
What does Nymox's (NYMXF) upgrade to OTCQB mean for investors?
When did NYMXF resume trading on the OTCQB Market?
What is Nymox's (NYMXF) current focus in medical treatment development?
What exchange was NYMXF listed on before moving to OTCQB?
